Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract -: A randomized, placebo-controlled, double-blind trial

被引:108
|
作者
de La Cal, MA
Cerdá, E
García-Hierro, P
van Saene, HKF
Gómez-Santos, D
Negro, E
Lorente, JA
机构
[1] Univ Madrid, Hosp Getafe, Dept Crit Care Med, Madrid 28905, Spain
[2] Univ Madrid, Hosp Getafe, Dept Med Microbiol, Madrid 28905, Spain
[3] Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England
[4] Royal Liverpool Childrens NHS Trust, Liverpool, Merseyside, England
[5] Univ Madrid, Hosp Getafe, Dept Radiol, Madrid 28905, Spain
[6] Univ Madrid, Hosp Getafe, Dept Pharm, Madrid 28905, Spain
关键词
D O I
10.1097/01.sla.0000154148.58154.d5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate whether selective digestive decontamination (SDD) reduces mortality from any cause, and the incidence of pneumonia among patients with severe burns. Summary Background Data: SDD is a prophylactic strategy to reduce infectious morbidity and mortality in critically ill patients. Two meta-analyses and a recent randomized controlled trial demonstrated a mortality reduction varying between 20% and 40%. But this technique has never been properly evaluated in severely burned patients. Methods: The design of this single-center trial was randomized, double blind, placebo controlled. Patients with burns greater than or equal to20% of total body surface and/or suspected inhalation injury were enrolled and assigned to receive SDD or placebo for the total duration of treatment in the burn intensive care unit (ICU). Results: One hundred seventeen patients were randomized and 107 were analyzed (53 in the SDD group and 54 in the placebo group). The ICU mortality was 27.8% in the placebo group and 9.4% in the SDD group in the burn ICU. Treatment with SDD was associated with a significant reduction in mortality both in the burn ICU (risk ratio 0.25; 95% CI 0.08 to 0.76) and in the hospital (risk ratio 0.28; 95% CI 0.10 to 0.80), following adjustment for predicted mortality. The incidence of pneumonia was significantly higher in the placebo group: 30.8 and 17.0 pneumonias per 1000 ventilation days (P = 0.03) in placebo and SDD group, respectively. Conclusions: Treatment with SDD reduces mortality and pneumonia incidence in patients with severe burns.
引用
收藏
页码:424 / 430
页数:7
相关论文
共 50 条
  • [1] Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients -: A randomized, double-blind, placebo-controlled, multicenter trial
    García, MS
    Galache, JAC
    Diaz, JL
    Cerdá, EC
    Blasco, JR
    Aguinaga, MAG
    Reiz, AN
    Marín, SR
    Cañaveral, JJO
    del Castillo, JAS
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (03) : 908 - 916
  • [2] PREVENTION OF NOSOCOMIAL INFECTION IN CRITICALLY ILL PATIENTS BY SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    ROCHA, LA
    MARTIN, MJ
    PITA, S
    PAZ, J
    SECO, C
    MARGUSINO, L
    VILLANUEVA, R
    DURAN, MT
    INTENSIVE CARE MEDICINE, 1992, 18 (07) : 398 - 404
  • [3] Selective decontamination of the digestive tract in multiple trauma patients - A prospective double-blind, randomized, placebo-controlled study
    Quinio, B
    Albanese, J
    BuesCharbit, M
    Viviand, X
    Martin, C
    CHEST, 1996, 109 (03) : 765 - 772
  • [4] Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients:: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination
    Garbino, J
    Lew, DP
    Romand, JA
    Hugonnet, S
    Auckenthaler, R
    Pittet, D
    INTENSIVE CARE MEDICINE, 2002, 28 (12) : 1708 - 1717
  • [5] Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination
    Jorge Garbino
    Daniel P. Lew
    Jacques-A. Romand
    Stéphane Hugonnet
    Raymond Auckenthaler
    Didier Pittet
    Intensive Care Medicine, 2002, 28 : 1708 - 1717
  • [6] Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial
    Alberda, Cathy
    Gramlich, Leah
    Meddings, Jon
    Field, Catherine
    McCargar, Linda
    Kutsogiannis, Demetrios
    Fedorak, Richard
    Madsen, Karen
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (03): : 816 - 823
  • [7] SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT IN NEUROSURGICAL INTENSIVE-CARE UNIT PATIENTS - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    KORINEK, AM
    LAISNE, MJ
    NICOLAS, MH
    RASKINE, L
    DEROIN, V
    SANSONLEPORS, MJ
    CRITICAL CARE MEDICINE, 1993, 21 (10) : 1466 - 1473
  • [8] Efficacy of prucalopride in critically ill patients with paralytic ileus: A pilot randomized double-blind placebo-controlled trial
    Jandee, Sawangpong
    Wetwittayakhlang, Panu
    Boonsri, Pattira
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (02) : 362 - 366
  • [9] Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomized double-blind placebo-controlled trial
    Shadnoush, Mahdi
    Zahedi, Hoda
    Norouzy, Abdolreza
    Sahebkar, Amirhossein
    Sadeghi, Omid
    Najafi, Atabak
    Hosseini, Saeed
    Qorbani, Mostafa
    Ahmadi, Arezoo
    Ardehali, Seyed Hossein
    Hosseinzadeh-Attar, Mohammad Javad
    PHYTOTHERAPY RESEARCH, 2020, 34 (12) : 3180 - 3188
  • [10] Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial
    Sanaie, Sarvin
    Ebrahimi-Mameghani, Mehrangiz
    Hamishehkar, Hadi
    Mojtahedzadeh, Mojtaba
    Mahmoodpoor, Ata
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 (09): : 827 - 833